Patents Assigned to Bioscience, Inc.
  • Compounds comprising self-immolative group
    Patent number: 10383949
    Abstract: Provided are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: August 20, 2019
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Tae Kyo Park, Sung Ho Woo, Sun Young Kim, Jong Un Cho, Doo Hwan Jung, Ji Young Min, Hyang Sook Lee, Yun Hee Park, Jeong Hee Ryu, Kyu Man Oh, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Jeon Yang
  • Methods for extracting keratin proteins
    Patent number: 10385095
    Abstract: Described herein are methods to produce keratin protein-based biomaterials, the parameters required to achieve improved extraction, the parameters required to improve isolation, the parameters of lyophilization and the grinding process to achieve consistent particulate sizes of protein materials.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: August 20, 2019
    Assignee: Keratin Biosciences, Inc
    Inventors: Luke Burnett, Sarah Ann Boyd
  • Kits and devices for detecting analytes
    Patent number: 10384203
    Abstract: The invention provides devices that improve tests for detecting specific cellular, viral, and molecular targets in clinical, industrial, or environmental samples. The invention permits efficient detection of individual microscopic targets at low magnification for highly sensitive testing. The invention does not require washing steps and thus allows sensitive and specific detection while simplifying manual operation and lowering costs and complexity in automated operation. In short, the invention provides devices that can deliver rapid, accurate, and quantitative, easy-to-use, and cost-effective tests.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: August 20, 2019
    Assignee: First Light Biosciences, Inc.
    Inventors: Greg Yantz, Don Straus, Gordon Siek, Damon DeHart
  • Methods for determining resistance or susceptibility to HIV entry inhibitors
    Patent number: 10385411
    Abstract: The invention provides a method for determining whether a human immunodeficiency virus is likely to be more resistant to a viral entry inhibitor than a reference HIV. In certain aspects, the methods comprise comparing the length of one or more variable regions of an envelope protein of the HIV or a number of glycosylation sites on the envelope protein of the HIV to a length of one or more corresponding variable regions of an envelope protein of the reference HIV or a number of glycosylation sites on the envelope protein of the reference HIV, wherein the HIV is likely to be more resistant to the CD4 binding site entry inhibitor than the reference HIV when the HIV has longer variable regions than the reference HIV or the HIV has more glycosylation sites than the reference HIV.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: August 20, 2019
    Assignee: Monogram BioSciences, Inc.
    Inventor: Wei Huang
  • CELL-FREE PRODUCTION OF SUGARS
    Publication number: 20190249210
    Abstract: Provided herein, in some embodiments, are systems, methods, and compositions (e.g., cells and cell lysates) for enzymatically converting a polymeric glucose carbohydrate (e.g., starch) to sugar.
    Type: Application
    Filed: April 26, 2019
    Publication date: August 15, 2019
    Applicant: GreenLight Biosciences, Inc
    Inventors: Daniel MacEachran, Drew S. Cunningham, William Jeremy Blake, Matthew Eduardo Moura
  • METHODS AND PRODUCTS FOR PRODUCING ENGINEERED MAMMALIAN CELL LINES WITH AMPLIFIED TRANSGENES
    Publication number: 20190249199
    Abstract: Methods of inserting genes into defined locations in the chromosomal DNA of cultured mammalian cell lines which are subject to gene amplification are disclosed. In particular, sequences of interest (e.g., genes encoding biotherapeutic proteins) are inserted proximal to selectable genes in amplifiable loci, and the transformed cells are subjected to selection to induce co-amplification of the selectable gene and the sequence of interest. The invention also relates to meganucleases, vectors and engineered cell lines necessary for performing the methods, to cell lines resulting from the application of the methods, and use of the cell lines to produce protein products of interest.
    Type: Application
    Filed: January 25, 2019
    Publication date: August 15, 2019
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson
  • Hepatitis B core protein modulators
    Patent number: 10377748
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: August 13, 2019
    Assignees: Assembly Biosciences, Inc., Indiana University Research And Technology Corporation
    Inventors: William Turner, Lee Daniel Arnold, Hans Maag, Leping Li, Mark Bures, Simon Haydar, Samson Francis
  • Etanercept formulations stabilized with combinations of sugars and polyols
    Patent number: 10376588
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: August 13, 2019
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • NANOELECTROABLATION CONTROL AND VACCINATION
    Publication number: 20190239949
    Abstract: Techniques for treating a tumor and vaccinating against cancer are described. The techniques include treating the tumor by positioning electrodes over an interface between the tumor and non-tumor tissue and applying sub-microsecond pulsed electric fields. The positioning is facilitated by an imaginary contour line of a threshold value of the electric field. In an example, the imaginary contour line is overlaid over images that include the tumor such that the electrodes are properly positioned over the tumor. The techniques also include vaccinating against cancer by passing sub-microsecond pulsed electric fields through tumor cells of a subject sufficient to cause the tumor cells to express calreticulin on surface membranes. The tumor cells are extracted and introduced with the expressed calreticulin into the subject or another subject, thereby providing a vaccination.
    Type: Application
    Filed: April 15, 2019
    Publication date: August 8, 2019
    Applicant: Pulse Biosciences, Inc.
    Inventors: Richard Lee Nuccitelli, Jon Casey Berridge, Zachary Mallon, Mark Kreis, Brian Athos, Pamela Nuccitelli
  • Delivery of therapeutic agent
    Patent number: 10370663
    Abstract: A method of producing nanovesicles comprising an oligonucleotide inhibitor to an oncogene or a proto-oncogene or the gene product thereof, said method comprises a) introducing a DNA sequence encoding an oligonucleotide capable of inhibiting a human oncogenic or proto-oncogenic transcription factor, into a mammalian cell; b) allowing the cell to express said inhibitor oligonucleotide; and c) obtaining nanovesicles containing said inhibitor oligonucleotide from said cell. Nanovesicles produced by the claimed method can be effectively and specifically targeted to e.g. cancer cells to deliver the inhibitor oligonucleotide.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: August 6, 2019
    Assignee: Codiak BioSciences, Inc.
    Inventors: Jan Lötvall, Jonas Andrej Nilsson
  • KDM1A inhibitors for the treatment of disease
    Patent number: 10370346
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: August 6, 2019
    Assignee: Imago Biosciences, Inc.
    Inventors: John M. McCall, Hugh Y. Rienhoff, Jr., Michael Clare
  • Nucleic acid products and methods of administration thereof
    Patent number: 10369233
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: August 6, 2019
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • CO-STIMULATORY DOMAINS FOR USE IN GENETICALLY-MODIFIED CELLS
    Publication number: 20190233500
    Abstract: The present disclosure provides novel co-stimulatory domains useful in genetically-modified cells to promote cell proliferation and/or promote cytokine secretion after antigen recognition. For example, disclosed herein are genetically-modified cells comprising a chimeric antigen receptor or an inducible regulatory construct incorporating the co-stimulatory domains disclosed herein. Also disclosed herein are plasmids and viral vectors comprising a nucleic acid sequence encoding the co-stimulatory domains, and methods of administering compositions comprising the novel co-stimulatory domains to subjects in order to reduce the symptoms, progression, or occurrence of disease, such as cancer.
    Type: Application
    Filed: October 4, 2017
    Publication date: August 1, 2019
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, Aaron Martin, Jeffrey Sunman, Daniel T. MacLeod
  • SPATIOTEMPORAL REGULATORS
    Publication number: 20190233844
    Abstract: Provided herein, in some embodiments, are methods, compositions, systems and kits that enable spatiotemporal regulation of nucleic acid expression in engineered cells.
    Type: Application
    Filed: July 26, 2017
    Publication date: August 1, 2019
    Applicant: Senti Biosciences, Inc.
    Inventors: Timothy Kuan-Ta LU, Remus WONG
  • Isothermal methods for amplifying nucleic acid samples
    Patent number: 10364458
    Abstract: The description provides two-stage methods of nucleic acid amplification and detection reactions, which are useful for rapid pathogen detection or disease diagnosis. In particular, the description provides a method comprising a first-stage slow rate amplification reaction followed by a plurality of second-stage fast rate amplification reactions that are simultaneously monitored in real-time, and wherein a rapid rate of amplification is indicative of the presence of a site of interest.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: July 30, 2019
    Assignee: Tangen Biosciences, Inc.
    Inventors: John R. Nobile, John Davidson
  • Nucleic acid products and methods of administration thereof
    Patent number: 10363321
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: July 30, 2019
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Transgenic animal for production of antibodies having minimal CDRs
    Patent number: 10362770
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: July 30, 2019
    Assignee: Crystal Bioscience Inc.
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Fatty acid synthase inhibitor for use in the treatment of drug resistant cancer
    Patent number: 10363249
    Abstract: Compounds that are fatty acid synthesis modulators are provided. The compounds may be used in pharmaceutical compositions to treat taxane-resistant cancers. Methods are provided for treating taxane-resistant cancer in a subject. Methods are also provided for increasing the sensitivity of a cancer cell to taxanes (i.e., paclitaxel, Nab-paclitaxel docetaxel, and/or cabazitaxel) treatment.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: July 30, 2019
    Assignee: 3-V Biosciences, Inc.
    Inventor: Timothy Sean Heuer
  • Methods comprising dosing combinations for reducing undesired humoral immune responses
    Patent number: 10357483
    Abstract: Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: July 23, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
  • Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
    Patent number: 10357482
    Abstract: Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: July 23, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado